ArticleMedical oncology (Northwood, London, England)2013
KRAS gene mutations in correlation with clinicopathological features of colorectal carcinomas in Indian patient cohort.
Article in Medical oncology (Northwood, London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- Review
- A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.Molecular medicine (Cambridge, Mass.) · 2020Article
- KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis.Caspian journal of internal medicine · 2020Review
- Spatial heterogeneity ofCancer management and research · 2019Article
- Patterns and the Occurrence of KRAS Mutations in Metastatic Colorectal Cancers-a Study from Indian Regional Cancer Centre.Indian journal of surgical oncology · 2017Article
- Molecular spectrum ofJournal of gastrointestinal oncology · 2016Article
- Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.Medical oncology (Northwood, London, England) · 2014Article
- KRAS mutation profile differences between rectosigmoid localized adenocarcinomas and colon adenocarcinomas.Journal of gastrointestinal oncology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
KRAS gene mutations have been identified as a predictive molecular marker to predict the sensitivity of tumors to anti-EGFR therapeutics. The variability of clinical response to anti-EGFR agents has highlighted the need to select the appropriate patients who can benefit from the treatment. We examined the prevalence of KRAS mutations in 1,323 colorectal cancer patients from different regions of India and its correlation with geographic distribution and clinicopathological characteristics. DNA was extracted from formalin-fixed, paraffin-embedded tissue samples and was amplified by nested polymerase chain reaction at KRAS exon 2 and subjected to nucleotide sequencing using ABI 3100 Genetic Analyzer. The frequency of KRAS mutations was found to be 20.5 % (271/1,323). There was significant association (p < 0.05) between KRAS mutations, age and the tumor differentiation. Statistical analysis revealed significantly higher prevalence of colorectal cancer with mutated KRAS gene in northern regions of the country. No significant association was observed between KRAS mutations and gender (p > 0.05). Our study indicates that KRAS mutations in Indian colorectal cancer patients occur at lower level compared to that of Western population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.